Novo Nordisk A/S (NOVOb.CO): Here Wegovy again! (week 10)...Wegovy Pill TRx tracker. New TRx high despite strong rebound last week

Research evidence excerpt

Novo Nordisk A/S (NOVOb.CO): Here Wegovy again! (week 10)...Wegovy Pill TRx tracker. New TRx high despite strong rebound last week

Novo Nordisk A/S (NOVOb.CO)

19 June 2026 Citi Research

Maintain Neutral – We maintain our Neutral/High Risk rating. Although our 26E sales estimates are at the upper end of Novo

guidance, we think 27E will remain a difficult year with further sales/EPS declines and continue to see significant long-term

pricing/competitive uncertainty in Novo’s core obesity market.

Figure 1. Wegovy pill launch trajectory Figure 2. Wegovy franchise

© 2026 Citigroup Inc. No redistribution without Citigroup’s written permission. © 2026 Citigroup Inc. No redistribution without Citigroup’s written permission.

The above material includes information based on market research The above material includes information based on market research

information obtained under license from the following information information obtained under license from the following information

services: IQVIA Rapid Weekly, IQVIA National Prescription Audit™, Oct services: IQVIA Rapid Weekly, IQVIA National Prescription Audit™, Jan

2019-Jun 2026, Copyright IQVIA, All Rights Reserved. 2026-Jun 2026, Copyright IQVIA, All Rights Reserved.

Source: IQVIA Rapid Weekly, IQVIA National Prescription Audit™, Oct 2019- Source: IQVIA Rapid Weekly, IQVIA National Prescription Audit™, Jan 2026-

Jun 2026, Copyright IQVIA, All Rights Reserved., Citi Research Jun 2026, Copyright IQVIA, All Rights Reserved., Citi Research

Figure 3. Wegovy pill TRx by dose Figure 4. Wegovy pill TRx by dose as % total Wegovy pill

© 2026 Citigroup Inc. No redistribution without Citigroup’s written permission.

The above material includes information based on market research © 2026 Citigroup Inc.